July 18, 2025
| Today’s news and insights for biopharma leaders
UPDATED
The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed gene therapy Elevidys.
|
A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for hot flashes.
|
Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast start, according to HSBC.
|
News roundup
The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have become more difficult after the negative advisory committee vote.
|
UPDATED
Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said Thursday. But the details, and their potential consequences, are still not clear.
|
|
Real-world data (RWD) is crucial for healthcare decision-making. Learn best practices for maximizing regulatory, payer, HEOR and commercial impact through strategic data management in this playbook.
|
|
From Our Library
Playbook
Custom content for DNA Genotek
|
Playbook
Custom content for Cardinal Health
|
Webinar - on demand
Custom content for PurpleLab
|
Playbook
Custom content for Inovalon
|
View all resources
What We’re Reading
| 
